Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia
Genomic alterations have increasingly gained importance as prognostic markers in B-cell chronic lymphocytic leukemia (CLL).
The identification of genetic alterations of prognostic importance in CLL is accomplished currently using commercially available fluorescence in situ hybridization (FISH) panels that can detect the most common recurrent aberrations in CLL, involving chromosomes 11q, 13q, 14q, 17p and whole chromosome 12. [1] [2] [3] [4] Although the use of FISH analysis has improved the detection rate of genomic alterations in CLL from B50% using conventional cytogenetics to 480%, 5 there is a need for improved methods to identify prognostic markers that can aid in the risk-stratification of these patients. The identification of high-risk patients is essential for treatment planning and is of particular importance in earlystage, asymptomatic CLL patients, for whom rapid disease progression and a poor prognosis can be predicted by the presence of specific genomic abnormalities such as 11q and 17p deletions. [6] [7] [8] Recently, array comparative genomic hybridization (array CGH) has been gaining acceptance as a diagnostic tool that can also be applied to detect genomic gains and losses of prognostic importance in CLL, because of the advantages afforded by simultaneous genome-wide and locus-specific assessment of the leukemia with a single assay. [9] [10] [11] [12] [13] [14] Array CGH is well suited for the identification of genomic alterations of prognostic importance in CLL, because the most common and important aberrations are comprised of genomic losses and gains, whereas chromosomal translocations are relatively rare. Although translocations do occur in CLL, their prognostic significance is currently controversial. In a number of recent studies evaluating the use of array CGH as a clinical tool for genomic alteration detection in CLL, array CGH results have exhibited a high concordance with parallel FISH studies, except when FISH aberrations are present in less than B25-30% of the cells. [9] [10] [11] [12] [13] [14] In a recent report from our laboratory, we analyzed 174 cases of CLL by bacterial artificial chromosome (BAC)-based array CGH and found that we could identify correctly the aberrations identified by FISH 96% of the time. 12 The discordant results were because of small clonal cell populations that comprised o25-30% of the total sample. Interestingly, two CLL cases with cryptic (B1 Mb) 13q14 deletions detected by array CGH were missed by both of the 13q14 region FISH probes used in this study. These findings suggested that array CGH had advantages over FISH for the identification of certain types of genomic alterations in CLL. In this study, we present four additional CLL cases with atypical 11q deletions, including two cases that were not identified properly by a commercially available five-probe FISH panel that also included an 11q22.3 Vysis LSI ATM probe (Abbott Molecular, Des Plaines, IL, USA). This study is also the first to report CLL cases with large 11q deletions that do not include the ATM (Ataxia telangiectasia mutated) gene, suggesting that additional genes in this region may be important for the pathogenesis of CLL. Bacterial artificial chromosome array-based array GCH was used to detect recurrent genomic alterations in 190 cases of CLL using a clinically validated array designed to interrogate all known CLL prognostic loci. 11 This array contains 179 CLL prognostic marker probes along with a backbone of 914 FISH-mapped linearly distributed clones for wholegenome coverage at an average resolution of B2.5 Mb. This analysis identified 22 CLL cases with 11q deletions, with 20 cases that included the ATM gene in the deleted region. However, four of the CLL cases showed atypical 11q deletions, with two cases (Cases 1 and 2) exhibiting a centromeric breakpoint just proximal to the ATM locus, and two cases (Cases 3 and 4) exhibiting proximal breakpoints telomeric to the ATM gene (Figure 1 BAC array CGH analysis was performed using the HemeScan microarray (Combimatrix Molecular Diagnostics, Irvine, CA, USA). Differentially Cy3 and Cy5 fluorescence-labeled patient and normal sex-matched reference samples were co-hybridized to the microarray, scanned with a Gene-Pix 4000B microarray scanner and quantified using GenePix Pro microarray image analysis software (Molecular Devices, Sunnyvale, CA, USA). A loss of a particular clone is manifested as the simultaneous deviation of the ratio plots from a modal value of 1.0, with the red ratio plot showing a positive deviation (to the right), whereas the blue ratio plot shows a negative deviation at the same locus (to the left). Conversely, DNA copy number gains show the opposite pattern. A 'typical' 11q deletion involving the ATM gene is shown in the panel on the far left. Atypical 11q deletions involving the ATM gene near the proximal breakpoint of the deletion (Cases 1 and 2) and with proximal deletion breakpoints distal to the ATM gene (Cases 3 and 4).
(RP11-56J3-RP11-317A5; Figure 1 ). Although BAC array CGH suggested that the ATM gene might be involved directly in the proximal breakpoint region, further analysis using oligonucleotide array CGH revealed an 11.1 Mb deletion extending from 11q22.3-q23.3 that included the CUL5, ACAT, NPAT and ATM gene loci and STS markers D11S1828 and D11S1294 near the proximal breakpoint of the deletion (Figures 2a, 3 and Table 1 ). Oligonucleotide array analysis also confirmed the 2.4 Mb deletion of chromosome 13q14 identified by the BAC array. FISH analysis of this sample showed loss of LSI 13 (RB1) and LSI D13S319 on chromosome 13q14, and a LSI ATM probe also detected a deletion at the ATM locus on 11q23 (data not shown).
Bacterial artificial chromosome array CGH analysis of Case 2 revealed a number of large genomic alterations, including whole chromosome losses of chromosomes 1, 6, 13, 22 and X, as well as gain of the q-arm of chromosome 12 and loss of the p-arm of chromosome 17. Smaller alterations were also observed that included a gain of 5p15.33 and an B9 Mb deletion of 11q23 involving 11 clones at linear positions 107.57-116.62 (RP11-56J3-CTD-2213H23; Figure 1 ). Similar to Case 1, BAC array CGH suggested that the ATM gene might also be involved directly in the proximal breakpoint region. However, further analysis, using oligonucleotide array CGH, revealed an 9.41 Mb deletion extending from 11q22.3-q23.3 with a proximal breakpoint in the centromeric portion of the CUL5 gene that included the ACAT, NPAT and ATM gene loci, as well as the STS marker D11S1294 near the proximal breakpoint of the deletion (Figures 2b, 3 and Table 1 ). Oligonucleotide array analysis also confirmed the other alterations identified by BAC array CGH. FISH analysis of this sample showed gain of chromosome 12, loss of LSI 13 (RB1) and LSI D13S319 on chromosome 13, loss of LSI p53 on chromosome 17p, and a LSI ATM probe also detected a deletion at the ATM locus on 11q23 (data not shown). However, FISH analysis did not detect the other abnormalities identified in this case by array CGH on chromosomes 1, 5, 6, 22 and X.
Bacterial artificial chromosome array CGH analysis of Case 3 showed an B5 Mb deletion of 11q23 involving seven clones at linear positions 112.75-117.04 (CTD-2059P15-RP11-939C12) that did not include the ATM gene (Figure 1 ). Deletions of chromosomes 3p, 13q and 16p were also identified by the BAC array. Further characterization of this case, using oligonucleotide array CGH, revealed the 11q deletion to be 5.58 Mb in size with a proximal breakpoint distal to the ATM gene locus (Figure 2c and Table 1 ). This deletion was B4 Mb distal to the region interrogated by the B500 Kb LSI ATM FISH probe and, therefore, could not be detected by FISH analysis of this region of chromosome 11. Deletions of chromosomes 3p, 13q and 16p were also confirmed by oligonucleotide array analysis and found to be 8.8, 1.5 and 4.8 Mb in size, respectively.
Bacterial artificial chromosome array CGH analysis of Case 4 showed a relatively large 18 Mb deletion of 11q23 represented by the loss of 23 probes (RP11-54P20-RP11-378D7) at linear positions 108.97-124.95 (Figure 1 ). The two probes covering the ATM locus (RP11-56J3 and RP11-27I22) at linear positions 107.57 and 107.81 were proximal to the breakpoint and not included in the deletion. In addition to the 11q deletion, BAC array CGH revealed complex genomic alterations with losses on chromosomes 8p, 8q, 13q, 14q, 17p, 18p, 18q and a gain on 22q (data not shown). Oligonucleotide array CGH analysis, of this case, identified a 17.68 Mb deletion extending from 11q22.3-q24.2 ( Figure 2d and Table 1 ) and also confirmed the other genomic alterations detected by the BAC array. FISH analysis with a LSI ATM probe did not detect the 11q23 deletion, but additional FISH probes confirmed the genomic losses on 13q and 17p. Losses of chromosomes 8p, 8q, 14q, 18p, 18q and 22q were also not detected by FISH.
It has previously been assumed that the LSI ATM B500 Kb FISH probe provided adequate coverage for the detection of deletions of the 11q22.3q23 region in CLL. The protein encoded by the ATM gene is a cell cycle checkpoint kinase and upstream regulator of the p53 tumor suppressor, making it a potentially important target gene for deletion in cases of CLL with 11q deletions. Based on the biological role of the ATM gene and inclusion of the ATM gene locus, in all the earlier reported cases of 11q23 deletions in CLL, FISH analysis using the LSI ATM probe has become the accepted standard for evaluating 11q status in CLL and other hematological malignancies. 15, 16 However, the two CLL cases, reported in this study, with atypical 11q deletions that did not include the ATM gene, suggest that relying on only a single probe for the detection of a critical CLL prognostic genomic aberration may not be the best approach. Even recurrent aberrations such as those found in CLL are subject to breakpoint variability and unpredictable genomic rearrangements associated with tumorigenesis and clonal evolution. 17 FISH analysis of a large genomic region using a single probe less than a mega base in size, creates a situation in which important aberrations may not be identified properly. The genomic region interrogated by a single FISH probe will not always coincide with the actual abnormality present, or may not hybridize at breakpoints in which there is not enough overlap between the probe and the region containing the genomic aberration. In two of the CLL cases in this study (Cases 3 and 4), the LSI ATM FISH probe was unable to identify deleted regions telomeric to the region on 11q that was interrogated by this probe.
This study also defined a 2.94 Mb minimally deleted region on 11q in an array CGH analysis of 190 CLL samples that included 22 cases with 11q deletions. The minimally deleted region contains 18 protein-coding genes (Table 2) , and at least three of these genesFZW10, PLZF and TSLC1Fmay represent alternative targets to ATM for deletion in the 11q23 region. The ZW10 (zeste white 10 homolog) gene is a possible target for deletion because it encodes a protein involved in mitotic checkpoint signaling, and acts to ensure that proper chromosome segregation and stability is present during cell division. 18 This protein has also recently been suggested to be involved in acquired resistance to chemotherapy in melanoma cells. 19 Another possible target for deletion is the PLZF (promyelocytic leukemia zinc finger protein) gene. In a variety of cell models, expression of this gene has been associated with cell cycle arrest in the G 1 phase and eventual apoptosis. 20, 21 The transcriptional repressor protein encoded by the PLZF gene maintains cells in a Letters to the Editor quiescent state by repressing c-myc expression and preventing cell cycle progression. 22 A third possible target for deletion is the TSLC1 (tumor suppressor in lung cancer 1) gene. Deregulation of the TSLC1 tumor suppressor gene has been described in a number of human malignancies, including neuroblastoma, nasopharyngeal carcinoma, breast cancer, lung adenocarcinoma, high-grade gliomas, pancreatic adenocarcinoma, esophageal squamous cell carcinoma, some forms of primary gastric cancer and prostate cancer. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] The altered expression of TSLC1 has been associated with both promoter hypermethylation, as well as loss of heterozygosity. 25, 29, [30] [31] [32] Each of these three putative deletion target genes is located clearly within the minimally deleted region on 11q as determined by both BAC and oligonucleotide array CGH, in all four of the CLL cases with atypical 11q deletions included in this study. The ZW10, PLZF and TSLC1 genes were also deleted in all of the other 19 cases exhibiting 11q deletions in a recent CLL array CGH study from our laboratory. 11, 12 Further studies are needed to evaluate the possible association of losses of these genes with higher-risk subsets of CLL. However, this study suggests that the poor prognosis associated with 11q deletions in CLL may be due to alterations in the expression of a number of genes that contribute to cell growth control and genome integrity rather than owing to only a single gene. This study also indicates that BAC array CGH probes that contain the ZW10, PLZF and TSLC1 genes may be more reliable markers for the detection of 11q23 deletions in CLL than the LSI ATM FISH probe. Although deletion of the ZW10, PLZF and TSLC1 genes may contribute to an aggressive clinical course in cases of non-ATM 11q23-deleted CLL, it could alternatively be possible that 11q23 deletions that do not include the ATM gene may represent actually a subset of CLL, with a more favorable prognosis than the ATM-deleted cases. Further whole-genome studies correlating outcome in CLL cases with atypical 11q23 breakpoints are needed to further risk-stratify these patients. As array CGH becomes used more frequently to identify recurrent genomic LSI ATM Probe (~500 kb) Letters to the Editor alterations of prognostic significance in CLL, 14 identification of additional cases exhibiting atypical 11q23 deletions can be expected. Outcome studies for these patients will be critical to determine whether non-ATM deleted 11q23 cases should be stratified in a high-risk category or into a more favorable clinical category.
In the short time that high-throughput scanning of the CLL tumor genome by array CGH has been available for use by clinical laboratories, it has revealed rapidly the unexpected complexity and variability of genomic aberrations in CLL. Although FISH analysis has contributed tremendously to the molecular cytogenetic understanding of the CLL genome, it is clear that many important genomic aberrations may be missed by the currently available FISH prognostic marker panels. The increasing availability of array CGH for the assessment of CLL prognostic markers will allow simultaneous genome-wide and locus-specific analysis to become standard of care for CLL patients at the time of diagnosis, as well as for monitoring existing CLL cases for the acquisition of additional complex genomic alterations.
